Release Date:  December 31, 2001

NOTICE:  NOT-CA-02-007

National Cancer Institute

The National Cancer Institute's (NCI) Division of Cancer Control and 
Population Sciences (DCCPS) announces a limited competition for 
competing supplemental applications to NCI-funded research projects 
supported by R01, P01, P50, U01 and U19 grant mechanisms.   Most 
researchers who propose to develop and test cancer control 
interventions either explicitly or implicitly intend to disseminate the 
interventions within the populations from which the sample is drawn if 
the interventions prove efficacious. However, without financial support 
for the costs of dissemination, active dissemination rarely occurs.  
The purpose of these supplements is to fund the dissemination of 
promising intervention programs and products.  This includes 
interventions where statistical significance and potential public 
health/clinical significance suggest the merits of dissemination to the 
broader population from which the intervention study sample was 
originally drawn.  The supplement also may support cost-effectiveness 
evaluations of interventions, qualitative and quantitative research 
needed to adapt intervention products for use after formal research 
evaluation has ended and dissemination of intervention products.

These supplements have been designed to provide one-year funding to 
cancer control investigators whose intervention efficacy data have been 
analyzed, who are in the final years of their R01, P01, P50, U01 or U19 
awards.   Intervention research across the cancer control continuum 
that may be eligible for these supplements, includes: tobacco use 
prevention and cessation, promotion of appropriate changes in diet and 
physical activity, reduction of sun exposure and UV radiation exposure, 
facilitating informed decisions about genetic testing for cancer 
susceptibility, enhancing screening for breast, cervix and colorectal 
cancers, quality of care as well as improving coping skills and quality 
of life for cancer survivors and their families.

Detailed instructions for applying for this supplement can be found at:

Requests should contain enough detail to allow assessment of the 
scientific merit of the proposed dissemination plans and the 
appropriateness of the request for supplemental funding.  Budgets 
should not exceed $100,000 in direct costs for a time period not 
exceeding 12 months.  If there are extenuating circumstances that 
require a marginally larger budget, these should be well documented and 
justified.  All requests require an itemized budget and must be 
countersigned by the grantee institution's business office.  Requests 
for supplements under this program must comply with NIH policies for 
inclusion of women, minorities, and children in research involving 
human subjects.

Submissions may be made to this supplement no earlier than 24 months 
prior to the end of the last year of a currently funded NCI 
intervention research R01, P01, P50, U01 or U19 and no later than March 
28, 2002.  There must be an active parent grant during the entire 
funding period of the supplement.  Therefore, if the parent grant ends 
before 9/30/03, the grantee must apply for no-cost extension.  
Applicants with Type 2 awards can request a supplement to their Type 2 
award in order disseminate interventions tested in their Type 1 awards 
if, and only if, no resources were awarded in the type 2 grant for the 
dissemination of type 1 interventions.  In this particular case, the 
supplement (if awarded) will be linked to the Type 2 award to 
disseminate the evidence-based intervention tested in the original R01, 
P01, P50, U01 or U19 (Type 1) project.

Requests will undergo review for scientific merit by extramural 
reviewers with expertise in the cancer control intervention area and/or 
in dissemination and diffusion research.  Awards will be determined on 
the basis of scientific merit, program relevance, dissemination 
potential, and availability of funds.  Special consideration will be 
given to applications that plan to disseminate interventions tested in 
low income and ethnically diverse populations.

The earliest anticipated award date for this program will be September 
2002. Inquiries related to this notice should be addressed to the NCI 
Program Director for the particular R01, P01, P50, U01 or U19 for which 
the supplement is being requested.  Applicants are STRONGLY ENCOURAGED 
to discuss the efficacy data (e.g. effect sizes, consistency with prior 
research, relevance to target populations) supporting their competing 
supplement request from the original project with their respective NCI 
research project Program Director prior to submission.


Direct inquiries concerning the programmatic matters to:

Jon F. Kerner, Ph.D.
Assistant Deputy Director for Research Dissemination and Diffusion
Division of Cancer Control and Population Sciences
6130 Executive Boulevard
Executive Plaza North, Room 6144
Rockville, MD  20852
Telephone:  (301) 594-7294

Direct inquiries regarding fiscal matters should be made to:

Ms. Crystal Wolfrey
Grants Administration Branch
6120 Executive Boulevard
Executive Plaza South, Room 243
Rockville, MD  20852
Telephone:  (301) 496-8634

Direct inquiries regarding review matters to:

Referral Officer
Division of Extramural Activities
National Cancer Institute
6116 Executive Boulevard, Room 8041, MSC 8329
Bethesda, MD  20892-8329
Rockville, MD  20852 (for express/courier service)
Telephone:  (301) 496-3428
Fax:  (301) 402-0275

Return to Volume Index

Return to NIH Guide Main Index

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS) - Government Made Easy

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.